期刊文献+

地西他滨联合CAG方案治疗复发难治性急性髓系白血病的临床效果探析 预览

The clinical effect of diacetabine combined CAG in the treatment of recurrent refractory acute myeloid leukemia
在线阅读 下载PDF
收藏 分享 导出
摘要 目的研究地西他滨联合CAG方案治疗复发难治性急性髓系白血病的临床效果。方法随机选取本院收治的90例复发难治性急性髓系白血病患者(均为2017年6月至2018年6月期间)进行研究,根据抽签分组法将患者平均分为两组,对照组单用CAG方案进行治疗,而观察组联合使用地西他滨进行治疗,对两组疗效进行评估,并且观察两组治疗后不良反应发生情况,在治疗结束一年后对患者进行随访,记录两组存活与死亡情况。结果两组经不同方案治疗后,观察组联合治疗的疗效较对照组优越(95.56%>75.56%),并且观察组不良反应出现例数较对照组少(8.89%<26.67%),组间数据比较差异具有统计学意义(P<0.05)。并且治疗结束一年后,观察组存活率高于对照组,死亡率低于对照组,两组数据比较差异具有统计学意义(P<0.05)。结论在复发难治性急性髓系白血病患者治疗中,应用地西他滨联合CAG方案进行治疗,可有效提高患者疗效与安全性,故值得加大推广力度。 Objective To study the clinical effect of desitabine combined with CAG in the treatment of recurrent refractory acute myeloid leukemia. Methods Randomly selected our hospital 90 cases of recurrence of refractory acute myeloid leukemia patients(all are in June 2017 to June2018), according to the grouping of lottery patients, on average, will be divided into two groups, control group use the CAG solution treatment, the observation group treated with combination of his west marina, to evaluate curative effect of the two groups, and to observe adverse reactions occur, the two groups after treatment at the end of the treatment after a year of follow-up, in patients with records of two groups of live and death.Results After different treatment regimens, the combined treatment effect of the two groups was superior to that of the control group(95.56%>75.56%), In addition, the number of adverse reactions in the observation group was less than that in the control group(8.89%<26.67%), and the difference between the two groups was statistically significant(P<0.05). Moreover, one year after the end of treatment, the survival rate of the observation group was higher than that of the control group, and the mortality rate was lower than that of the control group. The difference between the two groups was statistically significant(P<0.05). Conclusion In the treatment of patients with recurrent refractory acute myeloid leukemia, the application of dioxetabine combined with CAG scheme can effectively improve the efficacy and safety of patients, so it is worthy of more promotion.
作者 刘春雨 栾岚 Liu Chunyu;Luan Lan(Dalian People' s Liberation Army 210th Hospital, Dalian, Liaoning, 116021, China)
出处 《当代医学》 2019年第14期23-26,共4页 Contemporary Medicine
关键词 地西他滨 CAG方案 复发难治性急性髓系白血病 Desitabine The CAG plan Recurrent refractory acute myeloid leukemia
  • 相关文献

参考文献10

二级参考文献43

共引文献32

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈